ClinicalTrials.gg
CompletedNCT00320541Updated Jul 22, 2013Results posted

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

A Phase 2 interventional study of gemcitabine and paclitaxel in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 32 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-22.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
21st of 90
187 · median 68
Started
2006
with 7 others
Phase 2
65 of 95
none open now
Registered
42nd of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 21st largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2006, is one of 65 in phase 2, and was the 42nd registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Cancer of Breast
  • Cancer of the breast
  • Breast Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females diagnosed with breast cancer and the cancer has spread to distant areas of the breast or organs.
  • Must be able to measure the disease by specific medical parameters
  • May have received breast cancer treatment in the early stage of the disease
  • May be restricted in physically strenuous activity but able to carry out light work.
  • Must have adequate organ function as seen in blood test results.

Exclusion criteria

Exclusion

Criteria:

  • Cancer that has spread to the brain.
  • Unstable heart problems
  • Unstable high blood pressure.
  • Breast cancer treatment after the disease has considered to spread to other areas or organs.
  • Unable to agree with the requirements of the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Active comparator
    paclitaxel plus bevacizumab (PB)

    paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days

    Drug: paclitaxel · Drug: bevacizumab

  • Experimental
    paclitaxel plus bevacizumab plus gemcitabine (PB+G)

    paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days

    Drug: gemcitabine · Drug: paclitaxel · Drug: bevacizumab

Interventions

  • 1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity

    Also known as: LY188011, Gemzar

  • 90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity

    Also known as: Taxol

  • 10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants qualified for tumor response analysis (per-protocol population).

    Time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment to measured progressive disease (PD) & post-therapy until PD or other therapy initiated (up to 35 months)

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was measured from date of randomization to first date of disease progression or death from any cause. For participants not known to have died or had disease progression as of data-inclusion cut-off date, PFS duration was censored at date of last study visit prior to data-inclusion cut-off date.

    Time frame: baseline to measured progressive disease or death up to 35 months (tumor assessments were performed every 2 cycles during study therapy; every 2 months during post-therapy until disease progression or new anticancer treatment initiated)

  2. Overall Survival

    Overall survival was measured from date of randomization to date of death from any cause. For participants not known to have died as of data-inclusion cut-off date, overall survival duration was censored at date of last study visit prior to the data cut-off date.

    Time frame: baseline to death from any cause (up to 35 months)

  3. Total Functional Assessment of Cancer Therapy -Breast (FACT-B): Change From Baseline to End of Therapy

    FACT-B measures the following domains of health-related quality of life (HR-QL): physical well-being (PWB), social/family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), \& additional concerns of breast cancer (BCS). Total FACT-B scores range from 0-144, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for FACT-B is 7-8 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

    Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)

  4. Physical Well Being (PWB) Subscale: Change From Baseline to End of Therapy

    The PWB subscale of FACT-B measures physical well-being. Total PWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

    Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)

  5. Social/Family Well Being (SFWB) Subscale: Change From Baseline to End of Therapy

    The SFWB subscale of FACT-B measures social/family well-being. Total SFWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

    Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)

  6. Emotional Well Being (EWB) Subscale: Change From Baseline to End of Therapy

    The EWB subscale of FACT-B measures emotional well-being. Total EWB scores range from 0 to 24, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

    Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)

  7. Functional Well Being (FWB) Subscale: Change From Baseline to End of Therapy

    The FWB subscale of FACT-B measures functional well-being. Total FWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

    Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)

  8. Breast Cancer Subscale (BCS): Change From Baseline to End of Therapy

    The BCS subscale of FACT-B measures additional concerns of breast cancer . Total BCS scores range from 0 to 36, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for BCS is 2-3 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

    Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)

  9. Trial Outcome Index-Breast (TOI-B): Change From Baseline to End of Therapy

    The TOI-B represents the total of the subscales PWB,FWB, and BCS. Total TOI-B scores range from 0 to 92, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for TOI is 5-6 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

    Time frame: Baseline through 30 days post therapy follow-up (up to 35 months)

07

Results

Posted Jul 27, 2010
Limitations and caveats
Of 191 randomized patients, 4 patients were disqualified from inclusion in any efficacy or safety analyses due to significant Good Clinical Practice (GCP) violations; data is reported for the remaining 187 randomized patients.

Participant flow

Participant flow — Overall Study
MilestonePaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Started9493
Completed4436
Not completed5057
Withdrew: Adverse event2119
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject1216
Withdrew: Physician decision913
Withdrew: Other34
Withdrew: Sponsor decision21
Withdrew: Death due to study disease13
Withdrew: Death due to adverse event(s)10
Withdrew: Protocol entry criterion not met10

Outcome measures

PrimaryOverall Response Rate (ORR)

Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants qualified for tumor response analysis (per-protocol population).

Time frame:
baseline & every 2 cycles (approximately 8 weeks) of treatment to measured progressive disease (PD) & post-therapy until PD or other therapy initiated (up to 35 months)
Reported as:
Mean · proportion of responders
Overall Response Rate (ORR)
proportion of respondersPaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Overall Response Rate (ORR)0.489 (0.385 to 0.595)0.587 (0.479 to 0.689)
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · Fisher Exact · p = 0.117 (Statistical significance at 0.05 level was required.)
SecondaryProgression-free Survival (PFS)

PFS was measured from date of randomization to first date of disease progression or death from any cause. For participants not known to have died or had disease progression as of data-inclusion cut-off date, PFS duration was censored at date of last study visit prior to data-inclusion cut-off date.

Time frame:
baseline to measured progressive disease or death up to 35 months (tumor assessments were performed every 2 cycles during study therapy; every 2 months during post-therapy until disease progression or new anticancer treatment initiated)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Progression-free Survival (PFS)8.8 (0.1 to 27.3)11.3 (1.5 to 33.8)
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · Log Rank · p = 0.247
SecondaryOverall Survival

Overall survival was measured from date of randomization to date of death from any cause. For participants not known to have died as of data-inclusion cut-off date, overall survival duration was censored at date of last study visit prior to the data cut-off date.

Time frame:
baseline to death from any cause (up to 35 months)
Reported as:
Median · months
Overall Survival
monthsPaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Overall Survival25.0 (0.1 to 34.6)24.3 (1.5 to 33.8)
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · Log Rank · p = 0.475
SecondaryTotal Functional Assessment of Cancer Therapy -Breast (FACT-B): Change From Baseline to End of Therapy

FACT-B measures the following domains of health-related quality of life (HR-QL): physical well-being (PWB), social/family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), \& additional concerns of breast cancer (BCS). Total FACT-B scores range from 0-144, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for FACT-B is 7-8 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

Time frame:
Baseline through 30 days post therapy follow-up (up to 35 months)
Reported as:
Mean · units on a scale
Total Functional Assessment of Cancer Therapy -Breast (FACT-B): Change From Baseline to End of Therapy
units on a scalePaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Total Functional Assessment of Cancer Therapy -Breast (FACT-B): Change From Baseline to End of Therapy-1.0 ± 15.10-10.8 ± 16.87
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · ANCOVA · p = 0.010ANCOVA model included treatment arm and baseline assessment.
SecondaryPhysical Well Being (PWB) Subscale: Change From Baseline to End of Therapy

The PWB subscale of FACT-B measures physical well-being. Total PWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

Time frame:
Baseline through 30 days post therapy follow-up (up to 35 months)
Reported as:
Mean · units on a scale
Physical Well Being (PWB) Subscale: Change From Baseline to End of Therapy
units on a scalePaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Physical Well Being (PWB) Subscale: Change From Baseline to End of Therapy-1.9 ± 5.90-4.0 ± 6.00
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · ANCOVA · p = 0.119ANCOVA model included treatment arm and baseline assessment.
SecondarySocial/Family Well Being (SFWB) Subscale: Change From Baseline to End of Therapy

The SFWB subscale of FACT-B measures social/family well-being. Total SFWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

Time frame:
Baseline through 30 days post therapy follow-up (up to 35 months)
Reported as:
Mean · units on a scale
Social/Family Well Being (SFWB) Subscale: Change From Baseline to End of Therapy
units on a scalePaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Social/Family Well Being (SFWB) Subscale: Change From Baseline to End of Therapy0.0 ± 3.43-1.9 ± 3.61
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · ANCOVA · p = 0.023ANCOVA model included treatment arm and baseline assessment.
SecondaryEmotional Well Being (EWB) Subscale: Change From Baseline to End of Therapy

The EWB subscale of FACT-B measures emotional well-being. Total EWB scores range from 0 to 24, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

Time frame:
Baseline through 30 days post therapy follow-up (up to 35 months)
Reported as:
Mean · units on a scale
Emotional Well Being (EWB) Subscale: Change From Baseline to End of Therapy
units on a scalePaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Emotional Well Being (EWB) Subscale: Change From Baseline to End of Therapy1.8 ± 3.17-0.2 ± 3.88
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · ANCOVA · p = 0.002ANCOVA model included treatment arm and baseline assessment.
SecondaryFunctional Well Being (FWB) Subscale: Change From Baseline to End of Therapy

The FWB subscale of FACT-B measures functional well-being. Total FWB scores range from 0 to 28, with higher scores representing better HR-QOL. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

Time frame:
Baseline through 30 days post therapy follow-up (up to 35 months)
Reported as:
Mean · units on a scale
Functional Well Being (FWB) Subscale: Change From Baseline to End of Therapy
units on a scalePaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Functional Well Being (FWB) Subscale: Change From Baseline to End of Therapy-0.3 ± 5.38-3.8 ± 4.71
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · ANCOVA · p = 0.004ANCOVA model included treatment arm and baseline assessment.
SecondaryBreast Cancer Subscale (BCS): Change From Baseline to End of Therapy

The BCS subscale of FACT-B measures additional concerns of breast cancer . Total BCS scores range from 0 to 36, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for BCS is 2-3 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

Time frame:
Baseline through 30 days post therapy follow-up (up to 35 months)
Reported as:
Mean · units on a scale
Breast Cancer Subscale (BCS): Change From Baseline to End of Therapy
units on a scalePaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Breast Cancer Subscale (BCS): Change From Baseline to End of Therapy-0.1 ± 5.02-1.9 ± 4.03
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · ANCOVA · p = 0.067ANCOVA model included treatment arm and baseline assessment.
SecondaryTrial Outcome Index-Breast (TOI-B): Change From Baseline to End of Therapy

The TOI-B represents the total of the subscales PWB,FWB, and BCS. Total TOI-B scores range from 0 to 92, with higher scores representing better HR-QOL. Minimally important differences estimates obtained for TOI is 5-6 points. FACT-B was assessed at baseline (prior to start of Cycle 1 \[Day 1\]), then prior to start of each subsequent cycle (approximately every 4 weeks) during therapy, through 30-day post therapy follow-up.

Time frame:
Baseline through 30 days post therapy follow-up (up to 35 months)
Reported as:
Mean · units on a scale
Trial Outcome Index-Breast (TOI-B): Change From Baseline to End of Therapy
units on a scalePaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Trial Outcome Index-Breast (TOI-B): Change From Baseline to End of Therapy-2.5 ± 12.53-9.1 ± 12.68
Statistical analysis
  • Paclitaxel Plus Bevacizumab (PB) vs Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G) · ANCOVA · p = 0.036ANCOVA model included treatment arm and baseline assessment.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel Plus Bevacizumab (PB)—27/94 (28.7%)93/94 (98.9%)
Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)—36/93 (38.7%)93/93 (100%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventPaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
Febrile neutropeniaBlood and lymphatic system disorders2/949/93
CellulitisInfections and infestations1/945/93
DehydrationMetabolism and nutrition disorders4/945/93
DyspnoeaRespiratory, thoracic and mediastinal disorders2/945/93
NeutropeniaBlood and lymphatic system disorders0/944/93
PyrexiaGeneral disorders2/944/93
LeukopeniaBlood and lymphatic system disorders1/943/93
Cardiac failure congestiveCardiac disorders0/943/93
Abdominal painGastrointestinal disorders3/941/93
Urinary tract infectionInfections and infestations3/941/93
Most frequent other events
Showing 10 of 74
Most frequent other events
EventPaclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)
FatigueGeneral disorders58/9474/93
NeutropeniaBlood and lymphatic system disorders39/9465/93
NauseaGastrointestinal disorders40/9458/93
Peripheral sensory neuropathyNervous system disorders49/9442/93
DiarrhoeaGastrointestinal disorders36/9447/93
AlopeciaSkin and subcutaneous tissue disorders41/9444/93
EpistaxisVascular disorders41/9440/93
ConstipationGastrointestinal disorders29/9437/93
AnaemiaBlood and lymphatic system disorders18/9435/93
StomatitisGastrointestinal disorders29/9433/93

Baseline characteristics

Age Continuous
Age Continuous(years)Paclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)Total
Mean57.5 ± 10.6856.8 ± 9.5657.2 ± 10.12
Sex: Female, Male
Sex: Female, Male(Participants)Paclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)Total
Female9493187
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Paclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)Total
Caucasian8077157
African51116
Hispanic7411
East Asian213
Region of Enrollment
Region of Enrollment(participants)Paclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)Total
United States9493187
Basis for Pathological Diagnosis
Basis for Pathological Diagnosis(participants)Paclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)Total
Histopathological8484168
Cytological10818
Missing011
Breakdown According to Eastern Cooperative Oncology Group (ECOG) Performance Status
Breakdown According to Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Paclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)Total
Fully Active- 05760117
Ambulatory, Restricted Strenuous Activity- 1373168
Missing022
Breakdown by Estrogen Receptor (ER) Status
Breakdown by Estrogen Receptor (ER) Status(participants)Paclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)Total
Positive6067127
Negative332558
Unknown112
Breakdown by Human Epidermal Growth Factor (HER-2 NEU) Status
Breakdown by Human Epidermal Growth Factor (HER-2 NEU) Status(participants)Paclitaxel Plus Bevacizumab (PB)Paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G)Total
Not done347
Positive426
Negative8786173
Missing011

13 further baseline measures are reported on the registry.

08

Study locations

32 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fayetteville, Arkansas 72703, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Jolla, California 92037, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mission Hills, California 91345, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Rosa, California 95403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Denver, Colorado 80218, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Myers, Florida 33916, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami Beach, Florida 33140, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33136, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32806, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30322, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Illinois 62703, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Muncie, Indiana 47303, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lexington, Kentucky 40536, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Southfield, Michigan 48075, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chesterfield, Missouri 63017, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Missoula, Montana 59807, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Akron, Ohio 44302, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dayton, Ohio 45429, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dunmore, Pennsylvania 18512, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pittsburgh, Pennsylvania 15213, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37916, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38138, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37203, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75237, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lubbock, Texas 79415, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond, Virginia 23230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Everett, Washington 98201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madison, Wisconsin 53717, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milwaukee, Wisconsin 53226, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00716, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00935, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Apr 2009 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2006
First posted
May 3, 2006
Start
May 2006
Primary completionActual
Apr 2009
CompletionActual
Aug 2012
Results first posted
Jul 27, 2010
Last update
Jul 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00320541
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
May 3, 2006
Start date
May 2006
Primary completion
Apr 2009
Completion
Aug 2012
Results posted
Jul 27, 2010
Last update
Jul 22, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion